Ebola

WHO Reports High Risk That Ebola May Spread From Congo

WHO Reports High Risk That Ebola May Spread From Congo

WHO reports two cases of the deadly virus were confirmed near the border with Uganda.

Two Ebola Patients Who Received Experimental Treatment Have Recovered

Two Ebola Patients Who Received Experimental Treatment Have Recovered

Two of the first 10 people to receive an experimental Ebola treatment have recovered from the highly dangerous disease.

Congo Approves Four More Experimental Ebola Therapies

Congo Approves Four More Experimental Ebola Therapies

Four more experimental treatments for Ebola virus have been approved by the Congo health ministry for use in an outbreak of the deadly infectious disease in the country's northeast.

Vaccinations Begin in Congo Ebola Outbreak

Vaccinations Begin in Congo Ebola Outbreak

First to be vaccinated will be health workers, contacts of confirmed Ebola patients

Thirteen Confirmed Ebola Cases in Latest Congo Outbreak

Thirteen Confirmed Ebola Cases in Latest Congo Outbreak

The number of confirmed cases in a new Ebola outbreak in Congo has reached 13, including three deaths.

New Ebola Outbreak in the Democratic Republic of Congo

New Ebola Outbreak in the Democratic Republic of Congo

Just a week after being declared Ebola-free, the DRC said that a new outbreak of the deadly virus has killed at least 20 people.

Evidence Exists for Persistence, Transmission of Ebola Virus

Evidence Exists for Persistence, Transmission of Ebola Virus

Outbreak report describes transmission of Ebola virus one year after survival of Ebola virus disease.

WHO: Congo Ebola Outbreak Over

WHO: Congo Ebola Outbreak Over

The latest Ebola outbreak in the Democratic Republic of Congo is over according to the WHO.

Eyes of Ebola Survivors Show Localized Pathological Changes

Eyes of Ebola Survivors Show Localized Pathological Changes

Survivors of Ebola virus disease have localized pathological changes in photoreceptors.

Single-Dose Ebola Vaccine Durable for 1 to 2 Years

Single-Dose Ebola Vaccine Durable for 1 to 2 Years

By

Study provides new data on the durability of the humoral immune response up to 2 years after single-dose injection with rVSV-ZEBOV vaccine in a population of primarily European ancestry, and additional data on durability at 1 year after vaccination in 2 African populations.

Evidence-Based Guidelines for Supportive Care in Ebola Treatment

Evidence-Based Guidelines for Supportive Care in Ebola Treatment

By

First-hand accounts of the care that was delivered during the 2013-16 West African outbreak of Ebola virus disease provided impetus for these guidelines.

Two Preclinical Ebola Vaccines Elicit Sustained Immune Responses

Two Preclinical Ebola Vaccines Elicit Sustained Immune Responses

Two vaccines to prevent Ebola virus disease demonstrated immune responses at 1 month.

Breadth of Viruses Detectable in Semen Examined

Breadth of Viruses Detectable in Semen Examined

A new research letter claims that 27 viruses can be found in human semen.

Ebola Vaccine Long-Term Safety and Antibody Response

Ebola Vaccine Long-Term Safety and Antibody Response

By

An Ebola virus vaccine, rVSVΔG-ZEBOV-GP, provided 100% protection against Ebola in a prior phase 3 trial. A new study reports long-term safety data and shows that the vaccine induces an antibody response for at least 1 year.

Novel Retinal Abnormality Seen in Ebola Survivors

Novel Retinal Abnormality Seen in Ebola Survivors

A small percentage of Ebola virus survivors have a novel retinal lesion as a result of the disease.

Ebola Outbreak: What to Consider if Experimental Vaccine Is Used

Ebola Outbreak: What to Consider if Experimental Vaccine Is Used

By

The number of suspected Ebola cases in the Democratic Republic of Congo has risen to 37.

Does HIV Coinfection Play a Role in Persistent Ebola RNA in Semen?

Does HIV Coinfection Play a Role in Persistent Ebola RNA in Semen?

Researchers discuss a case of an Ebola virus disease survivor with HIV coinfection whose semen tested positive for Ebola virus RNA 565 days after recovering from the disease.

Immunity Persists for Ebola Vaccines at One Year

Immunity Persists for Ebola Vaccines at One Year

A strategy of preemptive use of an AD26.ZEBOV followed by MVA-BN-Filo immunization schedule in at-risk populations may offer advantages over reactive use of single-dose vaccine regimens.

Blood Test May Determine Chance of Surviving Ebola Infection

Blood Test May Determine Chance of Surviving Ebola Infection

Changes in messenger RNA abundance proved to be a reliable means of predicting patient's chances of surviving Ebola virus disease.

New Ebola Vaccine Highly Effective in Preventing Spread of Disease

New Ebola Vaccine Highly Effective in Preventing Spread of Disease

By

A new vaccine for Ebola showed high efficacy in preventing the development of Ebola in clusters of people exposed to the virus, and protection was also conferred to those who were not vaccinated.

Despite Challenges, Liberia's Semen Screening Program for Ebola Successful

Despite Challenges, Liberia's Semen Screening Program for Ebola Successful

By

Liberia's Men's Health Screening Program for Ebola survivors successful in spite of complex challenges.

CDC Official Emphasizes Prevention as Data Show Ebola Virus Lingers in Semen

CDC Official Emphasizes Prevention as Data Show Ebola Virus Lingers in Semen

Virus is more likely to be found in male survivors older than 40, researchers report.

Investigational Ebola Vaccine Gets 'Breakthrough Therapy' Designation by FDA

Investigational Ebola Vaccine Gets 'Breakthrough Therapy' Designation by FDA

The FDA's Breakthrough Therapy Designation is intended to expedite the development and review of a candidate vaccine that is planned for use, alone or in combination, to treat a serious or life-threatening disease or condition.

What Role Did the CDC Play in the Ebola Response?

What Role Did the CDC Play in the Ebola Response?

CDC activated its Emergency Operations Center (EOC) for the Ebola response on July 9, 2014.

Ebola Virus Infection Control Measures Developed for Hospitals

Ebola Virus Infection Control Measures Developed for Hospitals

The CDC releases infection control measures implemented at a Texas hospital.

Some Ebola Survivors May Develop Visual Impairment

Some Ebola Survivors May Develop Visual Impairment

Approximately one-fifth developed severe or total vision loss within weeks of recovery.

Polyclonal Antibody-Based Product Protected Lab Animals Against Ebola

Polyclonal Antibody-Based Product Protected Lab Animals Against Ebola

By

Antibody is cost-effective, reducing economic burden that may result from this dangerous virus.

Early Clinical Trials Offer Promising Results for Ebola Vaccine

Early Clinical Trials Offer Promising Results for Ebola Vaccine

One vaccine provided first as a primer, and the second given as a booster.

American Academy of Neurology Officials Say Ebola May Leave Lasting Symptoms

American Academy of Neurology Officials Say Ebola May Leave Lasting Symptoms

Six months after active illness, headaches, memory loss, depression were still being reported.

Two Investigational Vaccines Show Promise for Ebola Virus Disease

Two Investigational Vaccines Show Promise for Ebola Virus Disease

Two vaccine candidates are well-tolerated and immunogenic in adult volunteers.

Sign Up for Free e-newsletters